# Giiant Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/giiant-pharma

- Industry: Biotechnology
- Headquarters: Montreal, Canada
- Website: www.giiant.com
- Total disclosed funding: $12M
- Latest round: Seed (Jun 30, 2021)
- Investors on record: 7

## About

Based in Canada, Giiant Pharma Inc. specializes in developing innovative drug therapeutics for inflammatory bowel diseases, leveraging gut-specific delivery mechanisms to enhance treatment efficacy.Giiant Pharma Inc., founded in 2014 and headquartered in Montreal, Canada, focuses on gut-restricted therapies for inflammatory bowel diseases. The company has completed a total of 3 deals, with the most recent funding round occurring on January 10, 2023, where they raised USD 500,000 from Crohn's & Colitis Foundation. CEO Christophe Mellon leads the company, which operates independently without known subsidiaries or parent firms.Giiant Pharma specializes in the development of gut-restricted, small molecule, tissue-specific drug therapeutics specifically designed for the treatment of inflammatory bowel diseases (IBD). Their core product offerings leverage an innovative Gastrointestinal-Induced Anti-inflammatory technology that utilizes the gut microbiota's bacterial activity to bioactivate and release active drug substances at targeted sites within the lower gastrointestinal tract. This precision delivery method ensures limited systemic absorption, thereby enhancing safety and local efficacy, which is critical for patients dealing with chronic conditions like IBD. The company’s products are primarily aimed at healthcare providers and specialty pharmacies within North America and Europe, focusing on improving the quality of life for patients suffering from IBD. Giiant Pharma's commitment to developing therapies that are tailored to individual patients addresses significant tolerability issues, enhancing treatment adherence and outcomes for users.Giiant Pharma generates revenue through strategic partnerships with healthcare providers and specialty pharmacies that facilitate the distribution of their proprietary therapeutic products. The transaction structure typically involves B2B agreements where Giiant Pharma collaborates with healthcare institutions to provide their drug candidates, ensuring targeted therapeutic delivery to patients. Pricing plans for their flagship products reflect the specialized nature of their therapies, which are designed to address specific gastrointestinal conditions while minimizing side effects. The company's approach to revenue generation emphasizes a partnership model, fostering long-term relationships with institutions that serve the IBD patient population. These partnerships not only enhance product accessibility but also facilitate ongoing research and development initiatives aimed at extending their therapeutic offerings in the future.In January 2023, Giiant Pharma Inc. raised USD 500,000 in venture funding from Crohn's & Colitis Foundation to support the development of GT-2108. The company aims to expand its product offerings and enhance its presence in targeted markets across North America and Europe, with plans to launch new therapeutics that address the complexities of inflammatory bowel diseases. The recent funding will play a crucial role in advancing these initiatives and solidifying Giiant Pharma's position in the therapeutic landscape.

## Funding rounds

- Seed, Jun 30, 2021, $1M — Quebec Consortium for Drug Discovery, AQC Capital
- Seed, May 19, 2021, $11M — Genesys Capital Management, Seido Capital, Fonds de solidarité FTQ Investissements, AmorChem, AQC Capital, Amplitude

## Investors

- Genesys Capital Management (https://capitalatlas.ai/funds/genesys-capital-management) — Seed
- Seido Capital (https://capitalatlas.ai/funds/seido-capital) — Seed
- Fonds de solidarité FTQ Investissements — Seed
- AmorChem (https://capitalatlas.ai/funds/amorchem) — Seed
- AQC Capital (https://capitalatlas.ai/funds/aqc-capital) — Seed
- Amplitude (https://capitalatlas.ai/funds/amplitude) — Seed
- Quebec Consortium for Drug Discovery — Seed